Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Prozac Pulvules · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | Fluoxetine Capsules 40 mg |
| 2 | ACTIVE_COMPARATOR | Prozac Pulvules 40 mg |
| Name | Type | Description |
|---|---|---|
| Fluoxetine Capsules 40 mg | DRUG | 40mg, single dose fasting |
| Prozac Pulvules 40 mg | DRUG | 40mg, single dose fasting |
Inclusion Criteria: 1. Age: 18 years and older. 2. Sex: Male and/or non-pregnant, non-lactating female. a. Women of childbearing potential must have negative serum beta human chorionic gonadotropin (b-HCG) pregnancy tests performed within 21 days prior to the start of the study and on the evening p...
Prozac Pulvules is a small molecule drug being studied in healthy volunteers. It is currently in Phase 1 clinical development, with a completed trial evaluating its pharmacokinetics. The drug is being developed by Viatris Inc. and is not yet approved for any indication.
Prozac Pulvules is developed by Viatris Inc., a company traded on the NASDAQ under the ticker symbol VTRS. The drug is currently in Phase 1 clinical development, with one completed trial in healthy volunteers.
Prozac Pulvules is in Phase 1 clinical development. It has one completed trial, NCT00649636, which enrolled 32 healthy volunteers in the United States. The drug is investigational and has not been approved by regulatory authorities.
Prozac Pulvules has one completed clinical trial, NCT00649636, titled "Fasting Study of Fluoxetine Capsules 40 mg and Prozac Pulvules 40 mg." This Phase 1 study enrolled 32 healthy volunteers in the United States and was active-controlled, though not double-blinded.
Prozac Pulvules is a formulation of fluoxetine, as indicated by the clinical trial comparing fluoxetine capsules 40 mg to Prozac Pulvules 40 mg. The drug is being studied in healthy volunteers and is currently in Phase 1 development by Viatris Inc.